Inclusion Criteria:

          1. Aged 18 or over

          2. Diagnosis of hepatocellular carcinoma. If primary diagnosis of HCC: diagnosis based on
             the following criteria:

               -  cyto-histological criteria, OR

               -  radiological criteria: Focal lesion >1 cm with arterial hypervascularization in 2
                  coincident imaging techniques (CT, MRI, or US), OR

               -  combined criteria: one imaging technique showing a focal lesion 1-2 cm with
                  arterial hypervascularization AND AFP levels >400 ng/mL, OR

               -  combined criteria: one imaging technique showing a focal lesion >2 cm with
                  arterial hypervascularization AND AFP levels >200 ng/mL

          3. Child-Pugh A and B up to 7 points (in patients receiving anticoagulant therapy;
             Child-Pugh score up to 5 points; INR category not regarded for calculation of the
             Child-Pugh score)

          4. Progression or intolerance to first line therapy - N.B: Date of patients last dose of
             therapy must be more than 28 days before enrolment into this study.

          5. ECOG Performance status 0, 1 or 2.

          6. Adequate organ function as defined by:

               -  Adequate hematologic function (ANC 1.0x109/l, platelet count 50x109/l, and
                  hemoglobin 9g/dl).

               -  Serum creatinine concentration < 1.5 times the upper limit of normal (ULN) and/or
                  creatinine clearance >60 ml/min

               -  Bilirubin level < 1.5 X ULN

               -  PT-INR/PTT<1.5 x ULN

          7. For women of child-bearing potential (defined as women who have not undergone surgical
             sterilization with a hysterectomy, and/or bilateral oophorectomy, and are not
             postmenopausal, defined as ≥12 months of amenorrhea) must have a negative serum
             pregnancy test within 14 days prior to the first study drug administration Effective
             contraception must be used throughout the duration of the study and up to 30 days
             following the last dose of the investigational medicinal product (IMP). Effective
             forms of contraception include complete abstinence from sexual intercourse, double
             barrier methods (condom with spermicide in conjunction with use of an intrauterine
             device or condom with spermicide in conjunction with use of a diaphragm), birth
             control patch or vaginal ring, oral, injectable, or implanted contraceptives and
             surgical sterilization (tubal ligation or vasectomy). Sperm and ova donation are
             prohibited during the duration of the study and 30days after the last dose. 8. Written
             informed consent prior to initiation of any study procedures and willing and able to
             comply with the study schedule

        Exclusion Criteria:

          1. Previous treatment with:

               -  Study medication, any other JAK1 inhibitor and/or known hypersensitivity to the
                  study medication

               -  An investigational agent within 28 days prior to start of study treatment

          2. Serious concurrent medical or psychiatric illness, including serious active infection

          3. Uncontrolled ascites

          4. Uncontrolled hypertension

          5. History of organ transplant (including prior liver transplant)

          6. Diagnosis of HIV, congenital immune defect, any immunosuppressive therapy for
             autoimmune disease or inflammatory bowel disease

          7. Patients with active or latent tuberculosis

          8. Patients with active hepatitis C or active hepatitis B that requires treatment

          9. Patients who have received a live vaccine 30 days or fewer prior to enrolment as well
             as patients who intend to receive live vaccination during study participation or for
             three months after last dose administration

        8. Patients who have a history of unprovoked venous thromboembolism (VTE) prior to the
        diagnosis of malignancy 9. Pregnant or breast feeding women Other clinically significant
        co-morbidities that could compromise the subject's participating in the study